Drug intelligence / Profile preview

Panolase

Development stage: Unknown
Lead developer: Omnica Laboratories
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

Panolase is a digestive enzyme replacement therapy manufactured by Omnica Laboratories. It is a combination product containing pancreatin (providing amylase, lipase, and protease), hemicellulase, and purified bile extracts. Formulated as an enteric-coated tablet, it is indicated for the treatment of pancreatic insufficiency, aiding in the digestion of fats, proteins, and carbohydrates. It is contraindicated in patients with acute pancreatitis or acute exacerbations of chronic pancreatic disease.

Brand names: Panolase

Targets

GehA (Triacylglycerol lipase GehA)Xylanase (Endo-1,4-beta-xylanase)AMY (Pancreatic alpha-amylase)

Beyond the preview

Go deeper on Panolase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panolase.

Explore the full profile